The experimental oral therapy UCB0599 — now in clinical trials — improves motor coordination and reduces inflammation and levels of the disease-related protein alpha-synuclein in a mouse model of Parkinson’s disease. “This comprehensive package of [Parkinson’s]-relevant improvements supports the rationale of directly targeting misfolded [alpha-synuclein] with the small molecule minzasolmin…

UCB, a global pharmaceutical company, is looking for men and women with early-stage Parkinson’s disease who want to take part in a Phase 2 clinical study that will test UCB0599, an investigational small molecule that prevents alpha-synuclein protein from folding into a wrong shape and building up to…

UCB is partnering with Novartis to co-develop and potentially market UCB0599, a small molecule to inhibit misfolding of the alpha-synuclein protein now in a Phase 2 clinical trial enrolling people with Parkinson’s disease. The agreement also includes an option to co-develop UCB7853 — an antibody against alpha-synuclein —…

Aiming to improve the clinical outcomes of people with Parkinson’s disease, pharmaceutical company UCB is partnering with key U.K. and U.S. nonprofits to establish the Patient Engagement Council for Parkinson’s Research. UCB is teaming up with the Parkinson’s Foundation in the U.S. and Parkinson’s UK in launching…

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.   UCB’s experimental oral therapy UCB0599 was generally well tolerated in people with mild to moderate Parkinson’s disease…

UCB has announced the start of a Phase 1b clinical trial to evaluate the efficacy and safety of its therapeutic candidate UCB0599 for the treatment of Parkinson’s disease. This multicenter clinical trial will take place across the United States. Current treatments for Parkinson’s, which include…